Teva Pharmaceutical Industries Ltd.announced that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011. Shlomo Yanai, President and CEO of Teva said, This important transaction reinforces Teva’s long term strategy of building out our branded and specialty pharmaceuticals business through diversification and expansion of our product portfolio and pipeline, while enhancing our position as the worldwide leader in generics. Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women’s Health along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
Roche Looks to Expand its Drug Production in the US
How Language Barriers Impact Non-Native English Speakers in Healthcare
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Rina-S Shows Promise in Advanced Ovarian Cancer
Latest stories
Related stories
Roche Looks to Expand its Drug Production in the US
How Language Barriers Impact Non-Native English Speakers in Healthcare
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Rina-S Shows Promise in Advanced Ovarian Cancer
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
